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Abstract: The Mycobacterium sp. BRS2A-AR2 is an endophyte of the mangrove plant Rhizophora
racemosa G. Mey., which grows along the banks of the River Butre, in the Western Region of Ghana.
Chemical profiling using 1H-NMR and HRESI-LC-MS of fermentation extracts produced by the
strain led to the isolation of the new compound, α-d-Glucopyranosyl-(1→2)-[6-O-(l-tryptophanyl)-β-
d–fructofuranoside] or simply tortomycoglycoside (1). Compound 1 is an aminoglycoside consisting of
a tryptophan moiety esterified to a disaccharide made up ofβ-d-fructofuranose andα-d-glucopyranose
sugars. The full structure of 1 was determined using UV, IR, 1D, 2D-NMR and HRESI-LC-MS data.
When tested against Trypanosoma brucei subsp. brucei, the parasite responsible for Human African
Trypanosomiasis in sub-Saharan Africa, 1 (IC50 11.25 µM) was just as effective as Coptis japonica
(Thunb.) Makino. (IC50 8.20 µM). The extract of Coptis japonica (Thunb.) Makino. is routinely used as
laboratory standard due to its powerful antitrypanosomal activity. It is possible that, compound 1
interferes with the normal uptake and metabolism of tryptophan in the T. brucei subsp. brucei parasite.
Keywords: endophytes; mangroves; glycosides; trypanosomes; antiparasitics
1. Introduction
Carbohydrate-based natural products constitute a very potent group of compounds with promising
prospects as future drugs [1]. Currently, there are many carbohydrate natural product derived
compounds that are already drugs and these include: The polysaccharides, tragacanth (diarrhea
and constipation) [2], astragalus (cancer) [3], lentinan (cancer and hepatitis B) [4], tremella (cancer
and chronic bronchitis) [5,6], icodextrin (peritoneal dialysis) [7] and pentosan polysulfate (interstitial
cystitis) [8]; the oligosaccharides, lactulose (constipation and hepatic encephalopathy) [9], sucralfate
(active duodenal ulcers) [10]; and the monosaccharides, miglitol (anti-diabetic) [11] and meglumine
(excipient) [12].
Glycosylated natural products are defined as natural compounds where the carbohydrate part
(glycone), either monomers or oligomers of different structures, is covalently bound to another chemical
structure (aglycone). The aglycone encompasses natural product scaffolds such as terpenes, steroids,
alkaloids, ribosomal and non-ribosomal peptides, modified amino acids, polyketides, macrolides,
flavonoids, polyenes, coumarins, anthracyclines, iridoids and lignans [13–16]. Glycosides display
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very broad bioactivities because, part of their structures are composed of one or more stereocenter
laden sugar portions with numerous hydroxyls and other functionalities that confer increased drug
water solubility, increased bioavailability, decreased toxicity, effective drug targeting, bioactivity, strong
molecular targeting and organism specificity while the non-sugar portion or aglycones, represent
molecules that also have many bioactivities [17]. Glycosides have been shown to exhibit potent α- and
β-glucosidase inhibition (nojirimycin and acarbose) [18–20], antibacterial (streptomycin, erythromycin
A, vancomycin, gentamycin, amikacin, kanamycin, neomycin and bleomycin) [21–23], anticancer
(digoxin and biselyngbyaside) [24,25], antifungal (hassallidin A and B, and macrolide CE-108) [26–28],
antiparasitic (amphotericin B and paromomycin) [29–32] and antioxidant (floridoside) activities [33].
Biologically, carbohydrates are known to participate in energy storage and constitute a major component
of structural polymers in microbes, plants and invertebrates [34–37]. Furthermore, as a result of their
structural and chemical characteristics, they play many other key biological roles such as fertilization
signaling, pathogen recognition, cellular interactions and tumor metastasis [38–41]. Therefore, it may
be proposed that naturally occurring glycosides constitute a possible source of future antiparasitic,
antitumor, antiviral, anticoagulant, antioxidant and anti-inflammatory drugs.
In the last four years, we have collected several mangrove plants including Conocarpus erectus Linn.,
Laguncularia racemosa (L.) C.F. Gaertn. and Rhizophora racemosa G. Mey. from unexplored unique and
extreme environments in the Ghanaian Western, Volta, and Brong Ahafo Regional wetlands. From these
samples, we have isolated many cultivable strains of endophytic microbes (e.g., Penicillium herquei
strain BRS2A-AR, Cladosporium oxysporum strain BRS2A-AR2F, etc.) from the different plant parts
that in turn produce culture extracts, which show antiparasitic activity against the neglected tropical
parasites Trypanosoma brucei subsp. brucei strain 927/4 GUTat10.1, Leishmania donovani (Laveran and
Mesnil) Ross, Leishmania major (Yakimoff and Schokhor), Schistosoma mansoni (Sambon) and Trichomonas
mobilensis (U.S.A.: M776 [M776]). Among these mangrove endophytic strains was the Mycobacterium sp.
BRS2A-AR2 (GenBank ID: KT945161), isolated from the aerial roots of the Ghanaian mangrove plant,
R. racemosa. We have previously reported for the first time ever that, strain BRS2A-AR2 biosynthesizes
gold nanoparticles that are cytotoxic to HUVEC and HeLa cell lines [42].
The mangrove plant Rhizophora racemosa G. Mey. is a multi-stemmed rambling to columnar
stilt-rooted mangrove tree that grow up to about 30 m (100 ft.) tall but, appear to be shorter,
more branched and scrubby in marginal habitats [43,44]. The leaves are opposite, simple, bright green,
leathery, obovate, with generally curved surface, obtuse blunt apex with a minute lip folded under [45].
The lower surfaces of the leaves have evenly scattered tiny corky warts, which appear as black spots
on dried leaves. The flowers show flat, slightly hairy petals, which are stiff erect with non-reflexed
calyx lobes [46]. They have thick, short rounded bracteoles and rounded flower buds. The stem of the
axillary flowers branches up to six times, making a maximum cluster size of 128 [43,46].
The Mycobacteria are members of the Actinobacteria with characteristic rod-shapes and are mostly
gram-positive aerobes or facultative anaerobes. This genus includes pathogens known to cause serious
diseases in mammals (Table S1). The strain Mycobacterium sp. BRS2A-AR2 colonies used in the present
study were aerobic, gram reaction positive, yellowish orange, viscous and non-spore forming in an ISP2
agar medium. According to a phylogenetic analysis based on 16S rRNA gene sequencing, BRS2A-AR2
formed a distinct branch from other Mycobacterium species, notably from its nearest neighbors, making
it a new species [42]. The closest relatives of strain BRS2A-AR2 were Mycobacterium houstonense ATCC
49403T (99.1%; 12 nt differences at 1440 locations), Mycobacterium senegalense AY457081T (99.1%; 12 nt
differences at 1440 locations) and Mycobacterium pallens czh-8T Dq370008 (98.81%; 17 nt differences at
1434 locations). Mycobacterium houstonense is a non-tuberculous species rarely responsible for human
infection [47] and similarly for Mycobacterium pallens [48]. On the other hand, Mycobacterium senegalense
is responsible for Bovine farcy, which is a chronic suppurative granulomatous inflammation of the skin
and lymphatics of cattle and is seen mostly in sub-Saharan Africa [49]. We have not performed any
clinical microbiology tests to prove the pathogenicity of strain BRS2A-AR2 or otherwise. However,
BRS2A-AR2 has not been previously isolated from any diseased human or animal and given that the
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strain is an endophyte of a mangrove plant that produced a very distinct 16S rRNA gene sequence,
it has been safe to work with it so far.
Large scale culture of Mycobacterium sp. BRS2A-AR2 in ISP2 fermentation media at pH 5.0, 28 ◦C
and 220 rpm produced extracts which upon solvent partitioning by a modification of Kupchan’s method
gave four fractions hexane (FH), dichloromethane (FD), methanol/water (FM) and butanol/water (WB).
Phytochemical screening on thin-layer chromatography (TLC) plates using iodine tank, Dragendorff,
phosphomolybdic acid, antimony (III) chloride and Ninhydrin reagents showed the WB to contain
the most interesting metabolites. The fraction WB was therefore subjected to a Sephadex LH-20
size exclusion chromatography to give four fractions of which WB-SF4 was found to contain the
compound of interest. HPLC of WB-SF4 led to the isolation of the potent glycoside antitrypanosomal
compound (Figure 1), α-d-glucopyranosyl-(1→2)-[6-O-(l-tryptophanyl)-β-d–fructofuranoside] or
simply tortomycoglycoside (1) (2.3 mg/L). The structure of this new compound was determined using
a combination of 1D- and 2D-NMR techniques with high-resolution liquid chromatography tandem
mass spectrometry (HRESI-LC-MS) data and TLCs.
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Figure 1. Structure of α-D-Glucopyranosyl-(1→2)-[6-O-(L-tryptophanyl)-β-D-fructofuranoside] (1). 
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Figure 2. Key COSY (bold lines) and 13C-1H HMBC (single arrows) correlations for compound 1. 
Figure 1. Structure of α-d-Glucopyranosyl-(1→2)-[6-O-(l-tr l)- -d-fructofuranoside] (1).
2. Results
The compound 1 was obtained at tR of 20 min on reverse phase HPLC. Compound 1 is a light
yellow pungent oil when completely free of solvent. The HRESI-LC-MS of compound 1 gave m/z
529.2630 corresponding to molecular formula of C23H33N2O12+ (∆ = +0.06 ppm and 9 degrees of
unsaturation) for [M + H]+. An [M + Na]+ ion was also seen at m/z 551.2449 corresponding to the
molecular formula C23H32N2NaO12+ (∆ = +0.06 and 9 degrees of unsaturation), which further and
undoubtedly confirmed the mass of this new compound under electrospray ionization conditions
(Figure S2). Due to the presence of the many hydroxyl groups, compound 1 showed a prominent [M +
H − OH]+ at 511.2527 as the base peak indicating random facile loss of H2O from different parts of
the molecule. Compound 1 is an amino acid O-glycoside that belongs to the group of compounds
known as the glycoconjugates. Analysis of the 1H, 13C and multiplicity edited Pulsed Field Gradient
Heteronuclear Single Quantum Coherence (gHSQCAD) spectrum of 1, suggested the presence of five
quaternaries, 14 methine and four methylene carbons with no methyl groups. The 1H-NMR chemical
shifts δH 10.9 (1H, d, J = 2.9 Hz, NH-1), 7.22 (1H, d, J = 2.9 Hz, H-2), 7.59 (1H, d, J = 8.1 Hz, H-4),
6.97 (1H, ddd, J = 8.1, 7.0, 1.2 Hz, H-5), 7.06 (1H, m, H-6), 7.35 (1H, m, H-7), 3.02 (2H, dd, J = 15.3,
8.7 Hz, H2-8), 3.55 (1H, m, H-9) and 3.59 (2H, d, J = 2.3, 4.3 Hz, NH-9) together with the δC 124.2
(C-2), 109.1 (C-3), 127.2 (C-3a), 118.3 (C-4), 118.4 (C-5), 120.9 (C-6), 111.4 (C-7), 136.3 (C-7a), 26.9 (C-8),
54.5 (C-9) and 170.8 (C-10) provided direct evidence for the presence of the aromatic tryptophan
residue. Detailed analysis of the 1H-1H Homonuclear Correlation Spectroscopy (gCOSY) spectrum
showed correlations H-2/NH-1, H-4/H-5, H-6/H-7 and H-8/H-9, which were further supported by
similar 1H-1H Total Correlation Spectroscopy (2D-TOCSY) correlations, including H-2/NH-1, H-4/H-7,
H-5/H-6, H-6/H-4, H-7/H-4 and H-8/H-9 to further confirm the presence of a tryptophan moiety. Several
Pulsed Field Gradient 1H-13C Heteronuclear Multiple Bond Correlations (gHMBCAD) providing
connections between the isolated spin-systems of the aromatic tryptophan through quaternaries and
heteroatoms were observed and include C-2, C-3, C-3a, C-9 and C-10 to H2-8, C-3, C-3a, C-6 and C-7a
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to H-4, C-2, C-3, C-3a and C-7a to 1NH, C-3, C-3a and C-7a to H-2, C-3a, C-4 and C-5 to H-7, C-3a and
C-7 to H-5 and finally C-4, C-5 and C-7a to H-6.
In the 13C NMR spectrum, the presence of several peaks between 65–95 ppm suggested the
presence of sugar moieties in compound (1). The gHMBCAD correlations C-10 to H-5′ and H-6′ and
the chemical shifts of C-10 and C-6’′ provided direct proof of attachment of the tryptophan residue
to a sugar through an ester bond. The identities of the sugars were found to be β-d-fructofuranose
and α-d-glucopyranose after inspection of the chemical shifts, anomeric coupling constants, 1H-1H
Rotating-frame Overhauser Spectroscopy (ROESY) data, molecular modeled structure and chiral TLCs.
The β-d-fructofuranose ring had δC 62.2 (C-1’), 104.0 (C-2′), 77.2 (C-3′), 74.3 (C-4′), 82.5 (C-5′) and 62.1
(C-6′) corresponding to δH 3.41 (2H, d, J = 3.1 Hz, H-1′), 3.89 (1H, d, J = 8.3 Hz, H-3′), 3.79 (1H, t, J =
7.7 Hz, H-4′), 3.57 (1H, dt, J = 7.7, 2.2 Hz, H-5′) and 3.41 (2H, d, J = 2.3 Hz, H-6′), respectively. The gCOSY
correlation H-5′/H-4′ along with the 2D-TOCSY correlations H-4′/H-3′, H-5′/H-3′, H-5′/H-4′, H-6′/H-3′
and H-6′/H-4′ confirmed the continuous spin system of the β-d-fructofuranose residue while the
gHMBCAD correlations C-4′ to H-3′, C-5′ to H-3′, C-5′ to H-4′, C-1′ to H-3′ and C-6′ to H-4′ showed
the positions of quaternaries and heteroatoms in the ring. The gHMBCAD correlation C-2′ to H-1′′
helped to solve the rest of the structure, which was shown to be an α-d-glucopyranose ring after similar
examination of the sugar ring, which is explained above. The α-d-glucopyranose ring carbon chemical
shifts were δC 91.8 (C-1′′), 71.7 (C-2′′), 72.8 (C-3′′), 69.9(C-4′′), 72.9 (C-5′′) and 60.5 (C-6′′) and δH 5.19
(1H, d, J = 4.1 Hz, H-1′′), 3.20 (1H, dd, J = 9.7, 3.9 Hz, H-2′′), 3.49 (1H, t, J = 9.3 Hz, H-3′′), 3.14 (1H, t,
J = 9.4 Hz, H-4′′), 3.65 (1H, ddd, J = 9.7, 4.7, 2.4 Hz, H-5′′), 3.52 (1H, dd, J = 10.0, 4.8 Hz, H-6′′) and
3.50 (1H, dd, J = 10.0, 2.6 Hz, H-6′′), respectively. The gCOSY correlations H-2′′/H-1′′, H-4′′/H-5′′
and H-4′′/H-3′′ supported by many 2D-TOCSY correlations that include H-1′′/H-3′′, H-1′′/H-2′′,
H-4′′/H-5′′, H-2′′/H-5′′, H-4′′/H-6′′, H-2′′/H-3′′, H-4′′/H-2′′, H-5′′/H-2′′, H-2′′/H-4′′, H-5′′/H-4′′,
H-3′′/H-4′′, H-6′′/H-5′′, H-6′′/H-4′′, H-4′′/H-1′′, H-2′′/H-1′′, H-5′′/H-1′′ and gHMBCAD correlations
C-5′′ to H-1′′, C-4′′ to H-3′′, C-5′′ to H-4′′, C-2′′ to H-3′′ and C-6′′ to H-4′′ provided proof of structure
for the α-d-glucopyranose ring moiety in compound (1). The absence of correlations in the 1H-1H
ROESY data, indirectly confirms the disposition of the protons in both the β-d-fructofuranose and
α-d-glucopyranose rings.
Complete NMR data for Compound 1 is given in Table 1 while the raw data can be found in the
Supplementary Figures S4–12. In Figures 2–4, a visual representation of COSY, HMBC, 2D-TOCSY and
ROESY correlations are shown.
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Table 1. 1D and 2D-NMR spectroscopic data for compound (1) in DMSO-d6, in ppm. 
# δc mult  δH mult (J Hz) 
1H-1H 
COSY HMBC TOCSY 
1 NH  10.9, d (2.9) 2 C-2, C-3, C-3a, C-7a  
2 124.2, CH 7.22, d (2.9) 1NH C-3, C-3a, C-7a 1NH 
3 109.1, C     
3a 127.2, C     
4 118.3, CH 7.59, d (8.1) 5 C-3, C-3a, C-6, C-7a 5, 6,7 
5 118.4, CH 6.97, m 4 C-3a, C-7 4, 6, 7 
6 120.9, CH 7.06, m 7 C-4, C-5, C-7a 4, 5, 7 
7 111.4, CH 7.35, m 6 C-3a, C-4, C-5 4, 5, 6 
7a 136.3, C     
8 26.9, CH2 3.02, dd (15.3, 8.7) 3.32, dd (15.1, 4.4) 
8, 9 
8, 9 
C-2, C-3, C-3a, C-9, C-
10 9, 2 
9 54.5, CH 3.55, m 8  8 
9 
NH2  3.59, dd (2.3, 4.3)    
10 170.8, C     
1′ 62.2, CH2 3.41, d (3.1)  C-2′, C-3′ 3′, 4′, 6′ 
2′ 104.0, C     
3′ 77.2, CH 3.89, d (8.1)  C-1′, C-4′, C-6′ 4′, 5′  
Figure 3. Key TOCSY (bold lines) correlations for compound 1.
l  , ,     
 
 
 .        . 
 
 .        . 
 .          ,  . 
            
   . ,  .   , , ,   
 . ,  . ,  .   , ,   
 . ,      
 . ,      
 . ,  . ,  .   , , ,  , ,  
 . ,  . ,   ,  , ,  
 . ,  . ,   , ,  , ,  
 . ,  . ,   , ,  , ,  
 . ,      
 . ,  . ,  . , .  . ,  . , .  
,  
,  
, , , , 
 ,  
 . ,  . ,     
 
  . ,  . , .     
 . ,      
′ . ,  . ,  .   ′, ′ ′, ′, ′ 
′ . ,      
′ . ,  . ,  .   ′, ′, ′ ′, ′  
Figure 4. Key ROESY (double arrow) correlations for compound 1.
Table 1. D and 2D-NMR spectroscopic t f r c und (1) in DMSO-d6, in ppm.
# δc mult δH mult (J Hz) 1H-1H COSY HMBC TOCSY
1 NH 10.9, d (2.9) 2 C-2, C-3, C-3a, C-7a
2 124.2, CH 7.22, d (2.9) 1NH -3, C-3a, C-7a 1NH
3 109.1, C
3a 127.2, C
4 118.3, CH 7.59, d (8.1) 5 C-3, C-3a, C-6, C-7a 5, 6,7
5 118.4, CH 6.97, m 4 C-3a, C-7 4, 6, 7
6 120.9, CH 7.06, m 7 C-4, C-5, C-7a 4, 5, 7
7 111.4, CH 7.35, m 6 C-3a, C-4, C-5 4, 5, 6
7a 136.3, C
8 26.9, CH2
3.02, dd (15.3, 8.7)
3.32, dd (15.1, 4.4)
8, 9
8, 9 C-2, C-3, C-3a, C-9, C-10 9, 2
9 54.5, CH 3.55, m 8 8
9 NH2 3.59, dd (2.3, 4.3)
10 170.8, C
1′ 62.2, CH2 3.41, d (3.1) C-2′, C-3′ 3′, 4′, 6′
2′ 0 .0, C
3′ 77.2, CH 3.89, d (8.1) C-1′, C-4′, C-6′ 4′, 5′
4′ 74.3, CH 3.79, t (7.7) 5′ C-1′, C-5′, C-6′ 3′, 5′
5′ 82.5, CH 3.57, dt (7.7, 2.2) 4′ 3′, 4′
6′ 62.1, CH2 3.41, d (2.3) C-10 1′, 3′, 4′
1′′ 91.8, CH 5.19, d (4.1) 2′′ C-5′′, C-2′ 5′′, 2′′,
2′′ 71.7, CH 3.20, dd (9.7, 3.9) 1′′ 5′′, 3′′, 4′′, 1′′
3′′ 72.8, CH 3.49, t (9.7) 4′′ C-2′′, C-4′′ 5′′, 2′′, 4′′, 1′′
4′′ 69.9, CH 3.14, t (9.5) 3′′, 5′′ C-5′′, C-6′′ 5′′, 6′′, 2′′, 1′′
5′′ 72.9, CH 3.65, ddd (9.7, 4.7, 2.4) 4′′ 1′′, 2′′, 3′′, 4′′
6′′ 60.5, CH2
3.52, dd (10, 4.8,)
3.50, dd (10, 2.6) 5
′′, 4′′
Compound 1 showed very interesting and consistent results when tested against our laboratory
strain of T. brucei brucei. The IC50 value of 11.25 µM calculated for 1 was almost as effective as that
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of the routine laboratory standard Coptis japonica (IC50 8.20 µM). Detailed examination of the dose
response curve for 1 (Figure 5) showed the potential for this compound to be significantly lethal and
potent against T. brucei brucei cells.
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It is possible that, compound 1 described herein can affect the easy recognition of the amino acid
tryptophan within the extracellular matrix. Therefore, subsequent uptake of tryptophan, metabolism
of tryptophan and the incorporation of tryptophan into important enzymes such as proteases and
phospholipases that contribute to the normal functions of the T. brucei brucei parasite is perturbed [50,51].
3. Experimental Section
3.1. General Experimental Procedures
1D and 2D NMR data were recorded on a Bruker AVANCE III HD Prodigy (BRUKER, Sylvenstein,
Germany) at 500 and 125 MHz for 1H and 13C, respectively. This instrument was optimized for 1H
observation with pulsing/decoupling of 13C and 15N, with 2H lock channels equipped with shielded
z-gradients and cooled preamplifiers for 1H and 13C. The 1H and 13C chemical shifts were referenced to
the solvent signals (δH 2.50 (1H, p) and δC 39.52 ppm in DMSO-d6). High- l i mass spectrometry
data were measured using a ThermoScientific LTQXL-Discovery Orbitrap (Thermo Scientific, Bremen,
Germany) coupled to an Accela UPLC-DAD system. The following conditions were used for mass
spectrometric analysis: Capillary voltage 45 V, capillary temperature 320 ◦C, auxiliary gas flow rate
10–20 arbitrary units, sheath gas flow rate 40–50 arbitrary units, spray voltage 4.5 kV and mass range
100–2000 amu (maximum resolution 30,000). The ion source was normal electrospray ionization that
acts both in positive and negative modes. Semi-preparative HPLC purifications were carried out using
a Phenomenex Luna reverse-phase (C18 250 × 10 mm, L × i.d.) column connected to a Waters 1525
Binary HPLC pump Chromatograph with a 2998 photodiode array detector (PDA), column heater and
in-line degasser. Detection was achieved on-line through a scan of wavelengths from 200 to 400 nm.
This system was also used to record the UV profile for the compounds. IR was measured using a
PerkinElmer FT-IR (UATR Two) spectrometer. All solvents were HPLC grade. Sephadex LH-20 and
HP-20 resin were obtained from Sigma Aldrich (Munich, Germany).
3.2. Mangrove Plant Sample Collection
The Ghanaian mangrove plant R. racemosa was collected along the banks of the River Butre
in the Western Region of Ghana at GPS coordinates: 4◦49′43.73′N and 1◦54′50.84′W elevation 7 m;
eye altitude 437 m. The plant parts sampled were leaves, buds, submerged roots, aerial roots, aerial
stems, fruit shoots and flowers.
3.3. Isolation and Purification of the Endophytic Mycobacterium Strain
Isolation, purification, identification and laboratory cultivation of the Ghanaian Mycobacterium sp.
BRS2A-AR2 were previously described by us [42].
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3.4. Fermentation
An Autoclaved Erlenmeyer flask (250 mL) plugged with non-absorbent cotton wool containing
50 mL of ISP2 (10 g of malt extract, 4 g each of yeast extract and D-glucose) fermentation media in
distilled water with pH 5.0 was directly inoculated with spores of strain BRS2A-AR2 and incubated at
28 ◦C and 220 rpm for three days. This seed culture was subsequently used to inoculate nine autoclaved
1 L Erlenmeyer flasks, each containing 200 mL ISP2 media at pH 5.0 and plugged with non-absorbent
cotton wool. The 1 L flasks were incubated at 28 ◦C and 220 rpm for 21 days. Two days before the
culture incubation period was complete, autoclaved HP-20 resin was added at 50 g/L to each of the
flasks under sterile conditions and the flasks were returned to the incubator.
3.4.1. Extraction and Purification
The Mycobacterium sp. strain BRS2A-AR2 fermentation broth (1.8 L) was filtered through a
piece of glass wool under suction in a Buchner funnel to separate the supernatant from the mycelia.
The supernatant was extracted with EtOAc and the mycelia and HP-20 resin were placed in a 1 L flask
and extracted first with CH2Cl2 followed by MeOH. All extracts were combined and evaporated under
reduced pressure to obtain a total crude extract (5.90 g). The total crude extract was subjected to a
modification of Kupchan’s solvent partitioning process [52] that gave the four fractions FH (1.2 g),
FD (1.6 g), FM (0.50 g) and WB (2.3 g), with the compounds of interests concentrated in the FD and
WB fractions. The Kupchan solvent partitioning process is able to simplify subsequent purification
and isolation steps, chemical profiling and biological activity screening by separating the extract
components according to their polarities. Briefly, the total crude extract was suspended in 200 mL
of water and extracted three times over three consecutive days with CH2Cl2. The water layer was
subsequently, extracted with sec-butanol once. The sec-butanol layer was dried under vacuum to give a
butanol/water (WB) fraction and the remaining water layer discarded. The CH2Cl2 layer was dried
under vacuum and suspended in 90/10 mixture of water/methanol. The 90/10 water/methanol mixture
was extracted three times over three consecutive days with hexane. The hexane extract was dried
under vacuum to give fraction hexane (FH). The 90/10 water/methanol layer was phase adjusted to
50/50 water/methanol and extracted three times with dichloromethane. The dichloromethane layer was
dried under vacuum to give fraction dichloromethane (FD). Drying the 50/50 water/methanol layer
under vacuum gives fraction methanol/water (FM). The fraction FH is the least polar fraction whilst
WB is the most polar fraction. The WB fraction was then subjected to Sephadex LH-20 size exclusion
chromatography by gravity to obtain four fractions that were labeled WB-SF1-4. Phytochemical
screening with ninhydrin on TLC plates followed by 1H-NMR showed the compound of interest to be
concentrated in the WB-SF4 (0.34 g). Fraction WB-SF4 was therefore subjected to semi-preparative
HPLC separation and purification using a Phenomenex Luna C18 column (C18 250 × 10 mm, L × i.d.).
Gradients of Solvent A: H2O (0.1% HCOOH) and Solvent B: CH3CN (0.1% HCOOH; 100% A to 100%
B in 30 min and hold for 30 min) were used as eluents with column flow rates set at 1.5 mL/min to
afford compound 1 (2.5 mg, tR = 20.0 min).
3.4.2. α-d-Glucopyranosyl-(1→2)-[6-O-(l-tryptophanyl)-β-d-fructofuranoside] (1)
Light yellow pungent oil; IR (neat) νmax 3482, 3040, 2922, 2853 and 1783 cm−1; UV (H2O:CH3CN)
λmax 238, 284 and 395 nm; for 1H and 13C NMR data, see Table 1; mass spectrometry data is detailed
in Supplementary Figures S1 and S2.
3.4.3. Acid Hydrolysis of Compound 1
Compound 1 (1.5 mg) was dissolved in MeOH (2 mL) and 5 N HCl (1 mL). The mixture was
refluxed for 3 h. The solution was neutralized with NaOH, extracted with EtOAc and concentrated
under vacuum. The sugars in the aqueous phase were identified as fructose and glucose by comparative
TLC with standard sugars using the solvent system BuOH/EtOAc/2-propanol/HOAc/H2O (7:20:12:7:6).
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This acid hydrolysis further confirmed the identities of the two sugars present in the structure of
compound 1.
3.5. Bioassay Reagents
Fetal Bovine Serum (FBS), Roswell Park Memorial Institute (St. Louis, MO, USA); (RPMI) 1640,
Iscove’s Modified Dulbecco’s Media IMDM, M-199, 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic
acid (HEPES), YI-S, adult bovine serum (ABS), gentamycin, penicillin-streptomycin-l-glutamine (PSG),
artesunate, alamar dye, dimethyl sulfoxide (DMSO), sodium citrate, adenine, sodium bicarbonate
(NaHCO3), AlbuMax II, sodium chloride (NaCl), potassium chloride (KCl), sodium phosphate dibasic
(Na2HPO4), sodium phosphate monobasic (KH2PO4) and sodium hydroxide (NaOH), were purchased
from Sigma-Aldrich, MO, USA. All other chemicals and reagents were of analytical grade.
3.5.1. Compound Preparation for Bioassay
A stock solution of compound 1 was prepared at a concentration of 100 mM. This was achieved by
drying the compound with nitrogen gas and weighing on a balance (AND GH-120, A and D Company
Limited, Tokyo, Japan) to ascertain the mass of the compound. Compound 1 was dissolved in an
appropriate amount of DMSO to attain the desired concentration. The stock solution was vortexed (MSI
Minishaker. IKA Company, Osaka, Japan) and filter sterilized into a vial through 0.45 µm millipore
filters under sterile conditions and stored at −20 ◦C until use.
3.5.2. Cell Culture
The GUTat 3.1 strain of the bloodstream form of T. brucei parasites was used in this study. Parasites
were cultured in vitro according to the conditions established previously by Yabu et al. in 1998 [53].
Parasites were used when they reached a confluent concentration of 1 × 106 parasites/mL. Estimation of
parasitemia was done with the Neubauer counting chamber. Parasites were diluted to a concentration
of 3 × 105 parasites/mL with an IMDM medium and used for the drug assay.
3.5.3. In Vitro Viability Test for Trypanosome Parasites
The Alamar Blue assay was carried out on treated and untreated trypanosome parasites to
ascertain their viability. The assay was performed in a 96-well plate following the manufacturer’s
instructions, with modification. Briefly, 1.5 × 104 parasites were seeded with varied concentrations of
the compound ranging from 0 to 100 µM. Final concentrations of DMSO were kept at 0.1%. After the
incubation of parasites with or without the compound for 24 h at 37 ◦C in 5% CO2, 10% Alamar
Blue dye was added, and the parasites were incubated another 24 h in darkness. After a total of
48 h, the plate was read for absorbance at 540 nm using the Tecan Sunrise Wako spectrophotometer,
AUSTRIA GmbH. The trend curve was drawn to obtain a 50% inhibitory concentration (IC50) for
the compound.
4. Conclusions
The Ghanaian Mycobacterium sp. BRS2A-AR2 (GenBank ID: KT945161) was previously isolated
and characterized by our group from the aerial roots of the mangrove plant, R. racemosa. We also
reported for the first time ever that, strain BRS2A-AR2 biosynthesizes gold nanoparticles that are
cytotoxic to HUVEC and HeLa cell lines [42]. Herein we report that, the main metabolite produced in
liquid culture by the strain BRS2A-AR2 is an amino acid glycoside (α-d-glucopyranosyl-(1→2)-[6-O-
(l-tryptophanyl)-β-d-fructofuranoside]) that consists of a tryptophan moiety esterified to a disaccharide
made up of β-d-fructofuranose and α-d-glucopyranose rings. Compound 1, exhibited potent
antitrypanosomal effects when tested against the laboratory strain of T. brucei brucei. It is possible that,
compound 1 interferes with the normal uptake and metabolism of tryptophan in the parasite.
Supplementary Materials: The following are available online http://www.mdpi.com/1422-8599/2019/2/M1066/s1.
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